InvestorsHub Logo
Followers 229
Posts 21432
Boards Moderated 2
Alias Born 08/03/2006

Re: None

Tuesday, 10/11/2016 9:35:34 AM

Tuesday, October 11, 2016 9:35:34 AM

Post# of 1706
The prospective, independent, multi-institutional study conducted by the French Urological Association (AFU) was designed to evaluate HIFU hemiablation (treatment of the half of the prostate where the tumor is located, sparing the rest of the gland) as a primary treatment for localized, unilateral prostate cancer. In the study, 111 patients received focal hemiablation using EDAP’s Ablatherm® Robotic HIFU at 10 different clinical institutions.

http://ih.advfn.com/p.php?pid=nmona&article=72639151

Nice!

And when you least expect it? buyout. imo. smile


"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EDAP News